Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
Drug developers Retension Pharmaceuticals and TRex Bio have filed paperwork for U.S. initial public offerings, reinforcing the biotech pipeline for the fall IPO window. The listings are the latest in a string of biotech companies tapping public markets. The filings signal continued investor appetite for biotech innovation.
The Atomic take
Two IPO filings in the same fall window suggest public-market buyers are ready to fund clinical-stage drug developers again, which matters because a reopened window gives longevity and immune-focused startups a realistic path to raise the large sums their trials demand. Watch how these two price and trade in their first weeks, since a strong debut would likely pull more biotechs off the sidelines before year-end, while a weak one could slam the door just as quickly. Also worth tracking is where the money flows, and whether investors reward companies with near-term readouts over earlier-stage aging science.
Read the full story at Reuters →Know where humanity is headed.
Five forces, one investment thesis a day. Free, every weekday morning.
Get The Atomic Five